Barret Kalindjian, Ph.D., FRSC Cchem
Barret Kalindjian, Ph.D., FRSC Cchem
Barret Kalindjian, Ph.D., FRSC Cchem
Synthetic and Medicinal Chemist
Dr. Kalindjian is a synthetic and medicinal chemist with peptide/protein half-life extension expertise as well as vast, small- molecule drug discovery and development experience gained within numerous therapeutic areas. Dr. Kalindjian was formerly with Beecham Pharmaceuticals, CEO/Research Director at James Black Foundation Ltd and Head of Drug Discovery at Norgin
Jack Spitzberg, M.D.
Barret Kalindjian, Ph.D., FRSC Cchem
Barret Kalindjian, Ph.D., FRSC Cchem
Clinical Cardiologist
Dr. Spitzberg is a practicing Board-certified cardiologist and internist. He graduated magna cum laude from Harvard University, received his medical degree from Columbia University, with fellowships at Stanford University and the University of Colorado. He currently practices at Cardiology & Interventional Vascular
Clinical Cardiologist
Dr. Spitzberg is a practicing Board-certified cardiologist and internist. He graduated magna cum laude from Harvard University, received his medical degree from Columbia University, with fellowships at Stanford University and the University of Colorado. He currently practices at Cardiology & Interventional Vascular Associates and is affiliated with a number of hospital systems in Dallas, Texas
Hani “Tony” Sabbah, Ph.D.
Hani “Tony” Sabbah, Ph.D.
Hani “Tony” Sabbah, Ph.D.
Section Head, Cardiovascular Research, Henry Ford Health System
Dr. Sabbah is a professor of Medicine at Wayne State University and the Director of CV Research at the Henry Ford Health System, Detroit, MI. Dr. Sabbah is an expert in cardiovascular disease, and is internationally recognized for research and translational medicine contribu
Section Head, Cardiovascular Research, Henry Ford Health System
Dr. Sabbah is a professor of Medicine at Wayne State University and the Director of CV Research at the Henry Ford Health System, Detroit, MI. Dr. Sabbah is an expert in cardiovascular disease, and is internationally recognized for research and translational medicine contributions to understanding and treatment of heart failure syndrome
Christopher Kroeger M.D., MBA
Hani “Tony” Sabbah, Ph.D.
Hani “Tony” Sabbah, Ph.D.
Chris brings more than 20 years of experience leading, building, and advising development-stage therapeutic and medical device companies, combined with the expertise of a physician and scientist. Chris is the current CEO of MapLight Therapeutics. Chris previously served as the CEO of Cardioxyl Pharmaceuticals (sold to Bristol Myers Squ
Chris brings more than 20 years of experience leading, building, and advising development-stage therapeutic and medical device companies, combined with the expertise of a physician and scientist. Chris is the current CEO of MapLight Therapeutics. Chris previously served as the CEO of Cardioxyl Pharmaceuticals (sold to Bristol Myers Squibb for $2.1 billion). Chris was also previously the CEO of OvaScience. Earlier in his career, Chris led investing efforts as a Partner at The Aurora Funds, a venture capital firm focused on early-stage biotechnology and medical device companies and held positions at Genzyme and Decision Resources.